Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Nash Pharma Reports Positive Pre-Clinical Results

Stockhouse Editorial
0 Comments| November 2, 2018

Breathtec Biomedical Inc. (CSE: BTH, OTCQB: BTHCF, Forum), through its wholly-owned subsidiary Nash Pharmaceuticals Inc., announced this week that its lead compound for non-alcoholic steatohepatitis NP-160 showed positive results in a recently completed study investigating its therapeutic effects.

For more, click here.

Breathtec recently acquired Nash Pharmaceuticals, a company with a risk-reduced approach to drug development through drug re-purposing

FULL DISCLOSURE: Breathtec Biomedical Inc. is a paid client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.